ONCOmmunity

Treatment Strategy for Rectal Cancer Patients With Inguinal Lymph Node Metastasis.

By: Koji Ueta, Takeru Matsuda, Kimihiro Yamashita, Hiroshi Hasegawa, Junko Mukohyama, Masashi Yamamoto, Yoshiko Matsuda, Shingo Kanaji, Taro Oshikiri, Tetsu Nakamura, Satoshi Suzuki, Yoshihiro Kakeji

Division of Gastrointestinal Surgery, Department of Surgery, Kobe University Graduate School of Medicine, Kobe, Japan.
2019-07-27; doi: 10.21873/anticanres.13779

Abstract

Background/aim

To investigate the impact of inguinal lymph node dissection (ILND) following neoadjuvant chemoradiotherapy (NACRT) for rectal cancer patients with ILN metastasis.

Patients

Forty-three patients with rectal cancer underwent NACRT followed by curative surgery between January 2005 and December 2016. Seven patients underwent ILND after NACRT for clinically-positive ILN metastasis (ILND (+) group), while the remaining 36 did not receive ILND for clinically negative ILN metastasis (ILND (-) group). Their outcomes were retrospectively analyzed.

Results

Only one patient in the ILND (+) group had a local recurrence at six years after surgery. The 5-year recurrence-free survival was 100% and 65.4% in the ILND (+) and ILND (-) groups, respectively (p=0.09), and the 5-year overall survival was 100% and 83.2%, respectively (p=0.32).

Conclusion

ILND following NACRT seems effective for rectal cancer patients with ILN metastasis.